A PROTAC (Proteolysis Targeting Chimeric Molecule) is a protein degrader comprised of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand for target protein (target binder).The transfer of ubiquitin and degradation of the targeted protein will occur as a result of the connection between an E3 ligase and a target protein brought on by a PROTAC.
E3 ligases determine the specificity of the proteins by catalyzing the transfer of ubiquitin to the desired proteins. Cells have hundreds of E3 ligases, but only a small number of them have been successfully exploited in PROTACs, including VHL (the tumor suppressor protein for von Hippel-Lindau disease), CRBN (Cereblon), MDM2 (the mouse double minute 2 homologue), and IAP (inhibitor of apoptosis).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V51690 | β-Naphthoflavone-CH2-OH (β-NF-CH2-OH) | 2752755-32-9 | β-Naphthoflavone-CH2-OH (β-NF-CH2-OH) is a ligand for the aryl hydrocarbon receptor (AhR) E3 ligase. |
|
V3396 | Lenalidomide (Revlimid, CC5013) | 191732-72-6 | Lenalidomide(Revlimid, CC-5013) is a derivative of thalidomide approved in the United States in 2005 for the treatment for myeloma and blood disorders called myelodysplastic syndromes. |
|
V33447 | Lenalidomide hydrochloride | 1243329-97-6 | Lenalidomide HCl (formerly CC-5013; CC 5013; IMiD1; trade name Revlimid),the hydrochloride salt ofLenalidomide, is a derivative of thalidomide approved for use in the United States since 2005 in the treatment for myeloma and blood disorders called myelodysplastic syndromes. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
